Literature DB >> 25421284

Lung cancer. Dacomitinib: getting on target after negative ARCHER trial.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25421284     DOI： 10.1038/nrclinonc.2014.210

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Authors:  Pasi A Jänne; Sai-Hong I Ou; Dong-Wan Kim; Geoffrey R Oxnard; Renato Martins; Mark G Kris; Frank Dunphy; Makoto Nishio; Joseph O'Connell; Cloud Paweletz; Ian Taylor; Hui Zhang; Zelanna Goldberg; Tony Mok
Journal:  Lancet Oncol       Date:  2014-11-05       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.